<table>
<thead>
<tr>
<th>Guideline Page and Request</th>
<th>Panel Discussion/References</th>
<th>Institution Vote</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>ALL-D (1 of 8)</strong></td>
<td></td>
<td>YES</td>
</tr>
<tr>
<td>Internal request:</td>
<td></td>
<td>15</td>
</tr>
<tr>
<td>Comment to consider the</td>
<td>Based on the discussion, the</td>
<td></td>
</tr>
<tr>
<td>inclusion of rituximab to</td>
<td>panel consensus was to include</td>
<td></td>
</tr>
<tr>
<td>regimens for induction</td>
<td>rituximab to induction</td>
<td></td>
</tr>
<tr>
<td>therapy for Ph-positive,</td>
<td>regimens as an option for</td>
<td></td>
</tr>
<tr>
<td>CD20-positive ALL.</td>
<td>patients with Ph-positive,</td>
<td></td>
</tr>
<tr>
<td></td>
<td>CD20-positive ALL.</td>
<td></td>
</tr>
<tr>
<td><strong>ALL-D (1 of 8)</strong></td>
<td></td>
<td>15</td>
</tr>
<tr>
<td>Internal request:</td>
<td>Based on the discussion, the</td>
<td></td>
</tr>
<tr>
<td>Comment to consider the</td>
<td>panel consensus was to include</td>
<td></td>
</tr>
<tr>
<td>inclusion of bosutinib as</td>
<td>bosutinib as a TKI option</td>
<td></td>
</tr>
<tr>
<td>a TKI option for induction</td>
<td>in induction therapy for</td>
<td></td>
</tr>
<tr>
<td>therapy of Ph-positive ALL.</td>
<td>patients with Ph-positive</td>
<td></td>
</tr>
<tr>
<td></td>
<td>ALL. This is a category 2A</td>
<td></td>
</tr>
<tr>
<td></td>
<td>recommendation.</td>
<td></td>
</tr>
<tr>
<td><strong>ALL-D (1 of 8) and (7 of 8)</strong></td>
<td></td>
<td>15</td>
</tr>
<tr>
<td>Internal request:</td>
<td>Based on the discussion, the</td>
<td></td>
</tr>
<tr>
<td>Comment to consider the</td>
<td>panel consensus was to include</td>
<td></td>
</tr>
<tr>
<td>inclusion of the CALGB</td>
<td>the CALGB 10701 regimen as</td>
<td></td>
</tr>
<tr>
<td>10701 regimen as an</td>
<td>an option for patients with</td>
<td></td>
</tr>
<tr>
<td>induction therapy option</td>
<td>Ph-positive ALL. This is a</td>
<td></td>
</tr>
<tr>
<td>for Ph-positive ALL.</td>
<td>category 2A recommendation.</td>
<td></td>
</tr>
<tr>
<td><strong>ALL-D (2 of 8)</strong></td>
<td></td>
<td>15</td>
</tr>
<tr>
<td>Internal request:</td>
<td>Based on the discussion, the</td>
<td></td>
</tr>
<tr>
<td>Comment to consider the</td>
<td>panel consensus was to include</td>
<td></td>
</tr>
<tr>
<td>inclusion of rituximab with</td>
<td>“± rituximab” to the Linker</td>
<td></td>
</tr>
<tr>
<td>the Linker 4-drug regimen</td>
<td>4-drug regimen as an</td>
<td></td>
</tr>
<tr>
<td>for induction therapy of</td>
<td>induction therapy option for</td>
<td></td>
</tr>
<tr>
<td>Ph-negative ALL.</td>
<td>adult patients (&lt;65 y) with</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Ph-negative ALL.</td>
<td></td>
</tr>
<tr>
<td>Guideline Page and Request</td>
<td>Panel Discussion/References</td>
<td>Institution Vote</td>
</tr>
<tr>
<td>----------------------------</td>
<td>-----------------------------</td>
<td>------------------</td>
</tr>
<tr>
<td><strong>ALL-D (4 of 8)</strong></td>
<td></td>
<td>YES</td>
</tr>
<tr>
<td>Internal request:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Comment to consider the</td>
<td>Based on the discussion, the panel consensus was to include inotuzumab ozogamicin in combination with mini hyper-CVD as an option for patients (&lt;65y) with relapsed/refractory Ph-negative B-ALL. This is a category 2A recommendation.</td>
<td>15</td>
</tr>
<tr>
<td>inclusion of inotuzumab</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ozogamicin in combination</td>
<td></td>
<td></td>
</tr>
<tr>
<td>with mini hyper-CVD as an</td>
<td></td>
<td></td>
</tr>
<tr>
<td>option for patients with</td>
<td></td>
<td></td>
</tr>
<tr>
<td>relapsed/refractory Ph-</td>
<td></td>
<td></td>
</tr>
<tr>
<td>negative B-ALL.</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>ALL-D (7 of 8)</strong></td>
<td></td>
<td>YES</td>
</tr>
<tr>
<td>Internal request:</td>
<td>Based on the discussion, the panel consensus was to include inotuzumab ozogamicin in combination with mini hyper-CVD as an induction therapy option for patients (≥65y) with Ph-negative B-ALL. This is a category 2A recommendation.</td>
<td>15</td>
</tr>
<tr>
<td>Comment to consider the</td>
<td></td>
<td></td>
</tr>
<tr>
<td>inclusion of inotuzumab</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ozogamicin in combination</td>
<td></td>
<td></td>
</tr>
<tr>
<td>with mini hyper-CVD as an</td>
<td></td>
<td></td>
</tr>
<tr>
<td>induction therapy option</td>
<td></td>
<td></td>
</tr>
<tr>
<td>for patients (≥65y) with</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ph-negative B-ALL.</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>ALL-F</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>External request:</td>
<td>Based on a review of data and discussion, the panel did not use the language proposed in the submission. However, the panel supported adding the following language:</td>
<td></td>
</tr>
<tr>
<td>Submission from Adaptive</td>
<td>• 5th bullet:</td>
<td></td>
</tr>
<tr>
<td>Biotechnologies (9/13/19)</td>
<td>o 1st sub-bullet: “Notify lab if immunotherapy (such as rituximab, blinatumomab, or tisagenlecleucel) has been used.”</td>
<td></td>
</tr>
<tr>
<td>to update Minimal/Measurable Residual Disease Assesment (ALL-F) as indicated in the submission.</td>
<td>o Last sub-sub-bullet: “For some techniques, a baseline sample may be needed or helpful for the MRD assessment to be valid.”</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>